Innovent Biologics Inc
HKEX:1801

Watchlist Manager
Innovent Biologics Inc Logo
Innovent Biologics Inc
HKEX:1801
Watchlist
Price: 97.3 HKD 0.21%
Market Cap: 166.3B HKD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+2%
Revenue
Forecast
+26%
Operating Income
Forecast
N/A
Net Income
Forecast
N/A

Wall Street
Price Targets

Price Targets Summary
Innovent Biologics Inc

Wall Street analysts forecast Innovent Biologics Inc stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Innovent Biologics Inc is 99.15 HKD with a low forecast of 40.4 HKD and a high forecast of 131.25 HKD.

Lowest Forecast
Wall Street Target
40.4 HKD
58% Downside
Average Forecast
Wall Street Target
99.15 HKD
2% Upside
Highest Forecast
Wall Street Target
131.25 HKD
35% Upside
Lowest
Price Target
40.4 HKD
58% Downside
Average
Price Target
99.15 HKD
2% Upside
Highest
Price Target
131.25 HKD
35% Upside
Innovent Biologics Inc Competitors:
Price Targets
C
2487
Cutia Therapeutics
25% Upside
URGN
Urogen Pharma Ltd
70% Upside
J
600201
Jinyu Bio-Technology Co Ltd
11% Upside
4882
Perseus Proteomics Inc
123% Upside
C
2487
Cutia Therapeutics
25% Upside
URGN
Urogen Pharma Ltd
70% Upside
J
600201
Jinyu Bio-Technology Co Ltd
11% Upside
4882
Perseus Proteomics Inc
123% Upside
PRQR
ProQR Therapeutics NV
319% Upside
KMDA
Kamada Ltd
133% Upside
A
ARMP
Armata Pharmaceuticals Inc
210% Upside
N
4893
Noile-Immune Biotech Inc
136% Upside

Revenue
Forecast

Revenue Estimate
Innovent Biologics Inc

For the last 7 years the compound annual growth rate for Innovent Biologics Inc's revenue is 144%. The projected CAGR for the next 3 years is 26%.

144%
Past Growth
26%
Estimated Growth
Estimates Accuracy
3%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Innovent Biologics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Innovent Biologics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
17%
Average Beat
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Innovent Biologics Inc's stock price target?
Price Target
99.15 HKD

According to Wall Street analysts, the average 1-year price target for Innovent Biologics Inc is 99.15 HKD with a low forecast of 40.4 HKD and a high forecast of 131.25 HKD.

What is Innovent Biologics Inc's Revenue forecast?
Projected CAGR
26%

For the last 7 years the compound annual growth rate for Innovent Biologics Inc's revenue is 144%. The projected CAGR for the next 3 years is 26%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 281,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.